About: Poseltinib

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org:8891

Poseltinib (HM71224, LY3337641) is an experimental Bruton's tyrosine kinase inhibitor for the treatment of rheumatoid arthritis. It was developed by Hanmi Pharmaceutical and licensed to Eli Lilly. Phase II clinical trials began in August 2016 in patients with rheumatoid arthritis. Additional phase II trials are planned for treatment of lupus, lupus nephritis, Sjögren's syndrome, and other immunological conditions.

Property	Value
dbo:abstract	Poseltinib (HM71224, LY3337641) is an experimental Bruton's tyrosine kinase inhibitor for the treatment of rheumatoid arthritis. It was developed by Hanmi Pharmaceutical and licensed to Eli Lilly. Phase II clinical trials began in August 2016 in patients with rheumatoid arthritis. Additional phase II trials are planned for treatment of lupus, lupus nephritis, Sjögren's syndrome, and other immunological conditions. (en)
dbo:casNumber	1353552-97-2
dbo:fdaUniiCode	D01E4B1U35
dbo:pubchem	56644522
dbo:thumbnail	wiki-commons:Special:FilePath/Poseltinib.svg?width=300
dbo:wikiPageID	52971323 (xsd:integer)
dbo:wikiPageLength	3073 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1015354385 (xsd:integer)
dbo:wikiPageWikiLink	dbr:Rheumatoid_arthritis dbc:Experimental_drugs dbc:Phenylpiperazines dbr:Eli_Lilly dbr:Lupus dbr:Clinical_trials dbc:Pyrimidines dbr:Hanmi_Pharmaceutical dbc:Acrylamides dbr:Bruton's_tyrosine_kinase dbr:Sjögren's_syndrome dbr:Lupus_nephritis
dbp:c	26 (xsd:integer)
dbp:casNumber	1353552 (xsd:integer)
dbp:h	26 (xsd:integer)
dbp:iupacName	N-acrylamide (en)
dbp:n	6 (xsd:integer)
dbp:o	3 (xsd:integer)
dbp:pubchem	56644522 (xsd:integer)
dbp:smiles	C=CC=O (en)
dbp:synonyms	HM-7122; LY 3337641 (en)
dbp:unii	D01E4B1U35 (en)
dbp:wikiPageUsesTemplate	dbt:Infobox_drug dbt:Pharma-stub dbt:Reflist dbt:Fdacite
dcterms:subject	dbc:Experimental_drugs dbc:Phenylpiperazines dbc:Pyrimidines dbc:Acrylamides
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug
rdfs:comment	Poseltinib (HM71224, LY3337641) is an experimental Bruton's tyrosine kinase inhibitor for the treatment of rheumatoid arthritis. It was developed by Hanmi Pharmaceutical and licensed to Eli Lilly. Phase II clinical trials began in August 2016 in patients with rheumatoid arthritis. Additional phase II trials are planned for treatment of lupus, lupus nephritis, Sjögren's syndrome, and other immunological conditions. (en)
rdfs:label	Poseltinib (en)
owl:sameAs	wikidata:Poseltinib https://global.dbpedia.org/id/2YnDd dbr:Poseltinib
prov:wasDerivedFrom	wikipedia-en:Poseltinib?oldid=1015354385&ns=0
foaf:depiction	wiki-commons:Special:FilePath/Poseltinib.svg
foaf:isPrimaryTopicOf	wikipedia-en:Poseltinib
is dbo:wikiPageRedirects of	dbr:C26H26N6O3 dbr:HM71224
is dbo:wikiPageWikiLink of	dbr:C26H26N6O3 dbr:HM71224
is foaf:primaryTopic of	wikipedia-en:Poseltinib